Association between the severity of sepsis and the changes in hemostatic molecular markers and vascular endothelial damage markers

Shock

Volumn 23, Issue 1, 2005, Pages 25-29

  Iba, Toshiaki ^a   Kidokoro, Akio ^a   Fukunaga, Masaki ^a   Sugiyama, Kazuyoshi ^a   Sawada, Tomohiro ^a   Kato, Hisaaki ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antithrombin activity; D dimer; Organ dysfunction; Plasminogen activator inhibitor 1; Protein C activity; Severe sepsis; Soluble fibrin

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN; D DIMER; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN DEGRADATION PRODUCT; MOLECULAR MARKER; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; SOLUBLE FIBRIN; THROMBIN ANTITHROMBIN COMPLEX; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; DISEASE SEVERITY; ENDOTHELIUM LESION; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROSPECTIVE STUDY; RELIABILITY; SEPSIS; THROMBOCYTE COUNT; VASCULAR ENDOTHELIUM;

ADULT; AGED; ANTIPLASMIN; ANTITHROMBIN III; ANTITHROMBINS; AREA UNDER CURVE; BIOLOGICAL MARKERS; BLOOD CELL COUNT; BLOOD COAGULATION TESTS; ENDOTHELIUM, VASCULAR; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PEPTIDE HYDROLASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROC CURVE; SEPSIS; TIME FACTORS;

EID: 11444257317     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000144422.32647.b6     Document Type: Article

References (20)

1. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546-1554, 2003.
2. Wenzel RP: Treating Sepsis. N Engl J Med 347:966-967, 2002.
3. Iba T, Kidokoro A, Fukunaga M: Leukocyte and platelet adhesion induce microcirculatory disturbance in endotoxemic organ dysfunction. Jpn J Thromb Hemostas 12:32-38, 2001.
4. Bernard G, Vincent JL, Laterre PF, Bernard G, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: Recombinant human activated protein C worldwide evaluation in severe sepsis (PROWESS) study group: efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001.
5. Warren HS, Suffredini AF, Eichacker PQ, Munford RS: Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 347:1027-1030, 2002.
6. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference of Committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-874, 1992.
7. Vincent JL, de Mendonca A, Camtraome F, Moreno R, Takala J, Suter PM. Sprung CL, Colardyn F, Blecher S: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med 26:1793-1800, 1998.
8. Vervloet G, Thijs LG, Hack EC: Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 24:33-44, 1998.
9. Kidokoro A, Iba T, Fukunaga M, Yagi Y: Alterations in coagulation and fibrinolysis during sepsis. Shock 5:223-228, 1996.
10. Iba T, Kidokoro A: The role of the endothelium in changes in procoagulant activity in sepsis. J Am Coll Surg 187:321-329, 1998.
11. Matthay MA: Severe sepsis-a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med 344:759-762, 2001.
12. Gando S, Nanzaki S, Sasaki S, Aoi K, Kemmotsu O: Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Crit Care Med 26:2005-2009, 1998.
13. Quick G, Eisenberg P: Bedside measurement of D-dimer in the identification of bacteremia in the emergency department. J Emerg Med 19:217-223, 2000.
14. Pettila V, Pentti J, Pettila M, Takkunen O, Jousela I: Predictive value of antithrombin III and serum C-reactive protein concentration in critically ill patients with suspected sepsis. Crit Care Med 30:271-275, 2002.
15. Asakura H, Ontachi Y, Mizutani T, Kato M, Ito T, Saito M, Morishita E, Yamazaki M, Aoshima K, Takami A, Yoshida T, Suga Y, Miyamoto K, Nakao S: Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. Eur J Haematol 67:170-175, 2001.
16. Shorr AF, Thomas SJ, Alkins SA, Fitzpatrick TM, Ling GS: D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest 121:1262-1268, 2002.
17. Mesters RM, Helterbrand J, Utterback BG, Yan B, Chao YB, Fernandez JA, Griffin JH, Hartman DL: Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 28:2209-2216, 2000.
18. Iba T, Yagi Y, Kidokoro A, Fukunaga M, Fukunaga T: A clinical study of the increase in plasma levels of soluble thrombomodulin in patients with sepsis and organ failure. Surg Today 25:585-590, 1995.
19. Green J, Doughty L, Kaplan SS, Sasser H, Carcillo JA: The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure. Thromb Haemost 87:218-223, 2002.
20. Wada H, Yamamuro M, Inoue A, Shiku H, Sakuragawa N, Redl H, Peer G, Taylor FB Jr: Comparison of the responses of global tests of coagulation with molecular markers of neutrophil, endothelial, and hemostatic system perturbation in the baboon model of E. coli sepsis-toward a distinction between uncompensated overt DIC and compensated non-overt DIC. Thromb Haemost 86:1489-1494, 2001.